DRUG INDUCED LIVER INJURIES BY TICAGRELORSTATINSINTERACTION: A CASE REPORT

Anna Licata, Maurizio Soresi, Giuseppe Montalto, Antonietta Serruto, Filippo Alessandro Montalto, Maria Giovanna Minissale

Risultato della ricerca: Other

Abstract

Background: The anti-aggregant therapy with aspirin and inhibitor ofP2Y12 platelets receptor for ADP, such as ticagrelor, can be used to preventatherothrombotic events in patients with coronaric acute syndrome. Statinsare also recommended in these patients even if the safety profile is burdenedby the risk of drug interaction (CYP 3A4 inhibition by ticagrelor). Here, wereport a case of acute rabdomiolysis and hepatotoxicity in a woman witha recent myocardial infarction treated with ticagrelor 90 mg twice daily,aspirin 100 mg daily, atorvastatina 40 mg once daily.Methods: We report a case of 68 old Caucasian woman with a diagnosisof myocardial infarction and coronary percutaneous stenting treated withticagrelor and statins, complaining since the first month after dischargingof general illness, asthenia, nausea, myalgia, itching and epistaxis. For theaccentuation of these symptoms, in the following month she was admittedto our Division of Internal Medicine.Results: At admission, laboratory showed an eleveted value of CPK (100upper normal limits), eleveted cytolytic and cholestatic values (AST/ALT45-30 u.n.l, ggt 10 u.n.l, AP 2 u.n.l, bilirubin tot/ 4, 8 mg/dl), creatinine clearancewas 37, 3 mL/min/1, 73 m2. No history of alcohol or drug abuse wasreported; non-organ specific autoantibody (ANA, SMA, LKM) and viralserology (HAV, HBV, HCV, CMV, HSV) were negative. According consensuscriteria for Drug Induced Liver Injury (DILI) patient was diagnosed assuffering from a hepatocellular liver injury. RUCAM score was calculated as11 (highly probable). Assuming an episode of interaction due to ticagrelorand atorvatastin, we withdrawn immediately atorvastatin and continuedticagrelor with ASA. There was a clinical and biochemical improvement,with decrease of creatinkinase and aminotransferases till normal valueswithin 15 days. Intravenous fluids and albumin were administered to avoidacute kidney failure.Discussion and Conclusions: Drug-drug interaction between ticagrelorand atorvastatin caused certainly the development of muscle and liver injuries.Physician should be informed of the possibility that the ticagrelor/statinassociation even useful to prevent atherothrombotic events in patients withcoronaric acute syndrome could be cause muscle, liver and kidney injuries
Lingua originaleEnglish
Pagine117-117
Numero di pagine1
Stato di pubblicazionePublished - 2017

Fingerprint

Chemical and Drug Induced Liver Injury
Drug Interactions
Aspirin
Liver
Wounds and Injuries
Myocardial Infarction
Purinergic P2 Receptors
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Asthenia
Epistaxis
Muscle Development
Platelet Aggregation Inhibitors
Myalgia
Pruritus
Patient Safety
Internal Medicine
Transaminases
Bilirubin
Autoantibodies
Nausea

Cita questo

DRUG INDUCED LIVER INJURIES BY TICAGRELORSTATINSINTERACTION: A CASE REPORT. / Licata, Anna; Soresi, Maurizio; Montalto, Giuseppe; Serruto, Antonietta; Montalto, Filippo Alessandro; Minissale, Maria Giovanna.

2017. 117-117.

Risultato della ricerca: Other

Licata, Anna ; Soresi, Maurizio ; Montalto, Giuseppe ; Serruto, Antonietta ; Montalto, Filippo Alessandro ; Minissale, Maria Giovanna. / DRUG INDUCED LIVER INJURIES BY TICAGRELORSTATINSINTERACTION: A CASE REPORT. 1 pag.
@conference{7835298cab4a4277bf415b4f606b60a0,
title = "DRUG INDUCED LIVER INJURIES BY TICAGRELORSTATINSINTERACTION: A CASE REPORT",
abstract = "Background: The anti-aggregant therapy with aspirin and inhibitor ofP2Y12 platelets receptor for ADP, such as ticagrelor, can be used to preventatherothrombotic events in patients with coronaric acute syndrome. Statinsare also recommended in these patients even if the safety profile is burdenedby the risk of drug interaction (CYP 3A4 inhibition by ticagrelor). Here, wereport a case of acute rabdomiolysis and hepatotoxicity in a woman witha recent myocardial infarction treated with ticagrelor 90 mg twice daily,aspirin 100 mg daily, atorvastatina 40 mg once daily.Methods: We report a case of 68 old Caucasian woman with a diagnosisof myocardial infarction and coronary percutaneous stenting treated withticagrelor and statins, complaining since the first month after dischargingof general illness, asthenia, nausea, myalgia, itching and epistaxis. For theaccentuation of these symptoms, in the following month she was admittedto our Division of Internal Medicine.Results: At admission, laboratory showed an eleveted value of CPK (100upper normal limits), eleveted cytolytic and cholestatic values (AST/ALT45-30 u.n.l, ggt 10 u.n.l, AP 2 u.n.l, bilirubin tot/ 4, 8 mg/dl), creatinine clearancewas 37, 3 mL/min/1, 73 m2. No history of alcohol or drug abuse wasreported; non-organ specific autoantibody (ANA, SMA, LKM) and viralserology (HAV, HBV, HCV, CMV, HSV) were negative. According consensuscriteria for Drug Induced Liver Injury (DILI) patient was diagnosed assuffering from a hepatocellular liver injury. RUCAM score was calculated as11 (highly probable). Assuming an episode of interaction due to ticagrelorand atorvatastin, we withdrawn immediately atorvastatin and continuedticagrelor with ASA. There was a clinical and biochemical improvement,with decrease of creatinkinase and aminotransferases till normal valueswithin 15 days. Intravenous fluids and albumin were administered to avoidacute kidney failure.Discussion and Conclusions: Drug-drug interaction between ticagrelorand atorvastatin caused certainly the development of muscle and liver injuries.Physician should be informed of the possibility that the ticagrelor/statinassociation even useful to prevent atherothrombotic events in patients withcoronaric acute syndrome could be cause muscle, liver and kidney injuries",
author = "Anna Licata and Maurizio Soresi and Giuseppe Montalto and Antonietta Serruto and Montalto, {Filippo Alessandro} and Minissale, {Maria Giovanna}",
year = "2017",
language = "English",
pages = "117--117",

}

TY - CONF

T1 - DRUG INDUCED LIVER INJURIES BY TICAGRELORSTATINSINTERACTION: A CASE REPORT

AU - Licata, Anna

AU - Soresi, Maurizio

AU - Montalto, Giuseppe

AU - Serruto, Antonietta

AU - Montalto, Filippo Alessandro

AU - Minissale, Maria Giovanna

PY - 2017

Y1 - 2017

N2 - Background: The anti-aggregant therapy with aspirin and inhibitor ofP2Y12 platelets receptor for ADP, such as ticagrelor, can be used to preventatherothrombotic events in patients with coronaric acute syndrome. Statinsare also recommended in these patients even if the safety profile is burdenedby the risk of drug interaction (CYP 3A4 inhibition by ticagrelor). Here, wereport a case of acute rabdomiolysis and hepatotoxicity in a woman witha recent myocardial infarction treated with ticagrelor 90 mg twice daily,aspirin 100 mg daily, atorvastatina 40 mg once daily.Methods: We report a case of 68 old Caucasian woman with a diagnosisof myocardial infarction and coronary percutaneous stenting treated withticagrelor and statins, complaining since the first month after dischargingof general illness, asthenia, nausea, myalgia, itching and epistaxis. For theaccentuation of these symptoms, in the following month she was admittedto our Division of Internal Medicine.Results: At admission, laboratory showed an eleveted value of CPK (100upper normal limits), eleveted cytolytic and cholestatic values (AST/ALT45-30 u.n.l, ggt 10 u.n.l, AP 2 u.n.l, bilirubin tot/ 4, 8 mg/dl), creatinine clearancewas 37, 3 mL/min/1, 73 m2. No history of alcohol or drug abuse wasreported; non-organ specific autoantibody (ANA, SMA, LKM) and viralserology (HAV, HBV, HCV, CMV, HSV) were negative. According consensuscriteria for Drug Induced Liver Injury (DILI) patient was diagnosed assuffering from a hepatocellular liver injury. RUCAM score was calculated as11 (highly probable). Assuming an episode of interaction due to ticagrelorand atorvatastin, we withdrawn immediately atorvastatin and continuedticagrelor with ASA. There was a clinical and biochemical improvement,with decrease of creatinkinase and aminotransferases till normal valueswithin 15 days. Intravenous fluids and albumin were administered to avoidacute kidney failure.Discussion and Conclusions: Drug-drug interaction between ticagrelorand atorvastatin caused certainly the development of muscle and liver injuries.Physician should be informed of the possibility that the ticagrelor/statinassociation even useful to prevent atherothrombotic events in patients withcoronaric acute syndrome could be cause muscle, liver and kidney injuries

AB - Background: The anti-aggregant therapy with aspirin and inhibitor ofP2Y12 platelets receptor for ADP, such as ticagrelor, can be used to preventatherothrombotic events in patients with coronaric acute syndrome. Statinsare also recommended in these patients even if the safety profile is burdenedby the risk of drug interaction (CYP 3A4 inhibition by ticagrelor). Here, wereport a case of acute rabdomiolysis and hepatotoxicity in a woman witha recent myocardial infarction treated with ticagrelor 90 mg twice daily,aspirin 100 mg daily, atorvastatina 40 mg once daily.Methods: We report a case of 68 old Caucasian woman with a diagnosisof myocardial infarction and coronary percutaneous stenting treated withticagrelor and statins, complaining since the first month after dischargingof general illness, asthenia, nausea, myalgia, itching and epistaxis. For theaccentuation of these symptoms, in the following month she was admittedto our Division of Internal Medicine.Results: At admission, laboratory showed an eleveted value of CPK (100upper normal limits), eleveted cytolytic and cholestatic values (AST/ALT45-30 u.n.l, ggt 10 u.n.l, AP 2 u.n.l, bilirubin tot/ 4, 8 mg/dl), creatinine clearancewas 37, 3 mL/min/1, 73 m2. No history of alcohol or drug abuse wasreported; non-organ specific autoantibody (ANA, SMA, LKM) and viralserology (HAV, HBV, HCV, CMV, HSV) were negative. According consensuscriteria for Drug Induced Liver Injury (DILI) patient was diagnosed assuffering from a hepatocellular liver injury. RUCAM score was calculated as11 (highly probable). Assuming an episode of interaction due to ticagrelorand atorvatastin, we withdrawn immediately atorvastatin and continuedticagrelor with ASA. There was a clinical and biochemical improvement,with decrease of creatinkinase and aminotransferases till normal valueswithin 15 days. Intravenous fluids and albumin were administered to avoidacute kidney failure.Discussion and Conclusions: Drug-drug interaction between ticagrelorand atorvastatin caused certainly the development of muscle and liver injuries.Physician should be informed of the possibility that the ticagrelor/statinassociation even useful to prevent atherothrombotic events in patients withcoronaric acute syndrome could be cause muscle, liver and kidney injuries

UR - http://hdl.handle.net/10447/249375

UR - http://www.simi.it/download/SIMI_Volume%20Comunicazioni%20Orali%20e%20Poster.pdf

M3 - Other

SP - 117

EP - 117

ER -